Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility

Farmohammadi, Amir; Arab-Yarmohammadi, Vahid; Ramzanpour, Ramin

doi:10.31557/apjcp.2020.21.4.1167

Cited by 13 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that this study was designed as a retrospective study, the imaging evidence regarding the target lesions of the patients was collected and analyzed retrospectively. The best drug reaction assessment indicated that complete response (CR) was observed in 0 patients, partial response (PR) was noted in 75 patients, stable disease (SD) was seen in 42 patients, and progressive disease (PD) was reported in 11 Data cut-off date of this study was February 2021, and the median follow-up duration of the patients was 18.5 months (follow-up range: 0.5-36 months). Regarding PFS data, a total of 109 patients were observed the PFS events or death events when the data were cutoff.…”

Section: Influence Of Gstp1 Rs1695 Polymorphism On the Efficacy And Prognosis Of The Patientsmentioning

confidence: 99%

“…Among them, glutathione S-transferase P 1 (GSTP1) was the most widely studied isoform in various disease. 11 Glutathione S-transferase P 1 is located at 11q13.2, contains 7 exons and is of 3.2 kb in length with the ability to protect cells from carcinogens and cytotoxins. Discrepancy regarding the mRNA expression of GSTP1 gene was observed among different populations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study

Han

Tian

Jin

et al. 2021

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: This study was to investigate the influence of GSTP1 gene polymorphism on the clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy regimen. Methods: A total of 128 patients with advanced NSCLC who were administered with bevacizumab-based first-line regimens were recruited in this study. Available blood specimen and peripheral blood mononuclear cells (PBMCs) of the patients were obtained for the analysis of polymorphism and GSTP1 gene mRNA expression, respectively. The association between genotype status and clinical outcomes and other variates was analyzed and presented. Results: The prevalence of rs1695 were in accordance with Hardy-Weinberg Equilibrium ( P = .978). Patients with GG and AG genotypes were merged in a pattern of dominant inheritance to seek for the potentially clinical significance. Analysis of efficacy exhibited that the objective response rate (ORR) of patients with AA genotype and AG/GG genotypes were 62.1% (54/87) and 51.2% (21/41) ( P = 0.245). Prognosis demonstrated that the median progression-free survival (PFS) of patients with AA genotype and AG/GG genotypes were 9.5 and 5.6 months, respectively ( P = .007). Furthermore, the median overall survival (OS) of the two genotypes were 22.0 and 16.6 months, respectively ( P = .003). In addition, adjusted in multivariate Cox analysis for OS, AG/GG genotype was an independent factor for OS. Interestingly, mRNA analysis suggested that the mRNA expression of GSTP1 in PBMC of the patients with AG/GG genotypes of rs1695 polymorphism was significantly higher than those of patients with AA genotype ( P < .001). Conclusion: GSTP1 polymorphism rs1695 could be used for the prognostic evaluation of patients with advanced NSCLC receiving bevacizumab combined chemotherapy regimen.

show abstract

Section: Influence Of Gstp1 Rs1695 Polymorphism On the Efficacy And Prognosis Of The Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study

Han

Tian

Jin

et al. 2021

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“… 15 Among them, Glutathione S-Transferase P 1 (GSTP-1) is the most widely reported isoform in various diseases. 16 GSTP-1 is located at 11q13.2, contains 7 exons, and is 3.2kb in length with the ability to protect cells from carcinogens and cytotoxins. Individual difference was observed among different study populations.…”

Section: Introductionmentioning

confidence: 99%

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment

Zhi¹,

Wang²,

Xie³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Glutathione S-Transferase P 1 (GSTP-1) gene plays an important physiological role in the body. The present study was conducted to identify the clinical implication of GSTP-1 gene polymorphism on the prognosis of patients with high-grade glioma (HGG) who received temozolomide plus radiotherapy adjuvant treatment. Methods: This study recruited a total of 186 patients with HGG who were treated with temozolomide plus radiotherapy adjuvant regimen (retrospectively). Baseline clinical characteristics were obtained and the prognostic data of the patients were collected. Peripheral blood specimen of patients was preserved for genotyping of GSTP-1 polymorphism during hospitalization. Correlation analysis was carried out accordingly. Additionally, fresh peripheral blood specimens that were available for mRNA expression analysis were collected for the mRNA expression analysis. Results:The median progression-free survival (PFS) and overall survival (OS) of the 186 patients with HGG who received temozolomide plus radiotherapy regimen was 8.5 months (95% CI: 5.95-11.05) and 15.5 months (95% CI: 11.49-19.51), respectively. The prevalence of 313A>G among 186 patients with glioma was AA genotype: 126 cases (67.7%), AG genotype: 54 cases (29.1%), GG genotype: 6 cases (3.2%), minor allele frequency of 313A>G was 0.18. Association analysis suggested that the median PFS of patients with AA and AG/GG genotypes was 11.2 and 5.0 months, respectively (χ 2 =11.17, P=0.001). Furthermore, the median OS of patients with AA and AG/GG genotypes was 18.9 and 10.5 months, respectively (χ 2 =12.684, P<0.001). Besides, when adjusted for PFS in multivariate Cox regression analysis, AG/GG genotype was an independent factor for PFS (HR=0.48, P=0.006). The mRNA expression results indicated that mRNA expression of GSTP-1 in patients with AG/GG genotypes of 313A>G was significantly higher than that of patients with AA genotype (P<0.001). Conclusion: GSTP-1 polymorphism 313A>G might be used as a potential biomarker to predict the prognosis of patients with HGG who received temozolomide plus radiotherapy adjuvant treatment.

show abstract

“…Таким образом, результатом мутации являются генотипы GSTP1 Ile/Ile, Ile/Val и Val/Val. Замена изолейцина на валин в аминокислотной цепи приводит к снижению ферментативной активности белка, что потенциально снижает способность к детоксикации соединений [3].…”

Section: Introductionunclassified

The relationship of polymorphic variants of genes GSTM1, GSTT1, GSTP1 with the risk of developing diseases (literature review)

Amromina

Bereza

Shaikhova

2021

Hygiene and Sanitation

View full text Add to dashboard Cite

Authors analyzed the relationship of the most studied polymorphisms of glutathione-S-transferase genes (GSTT1, GSTM1, GSTP1) with the risk of developing diseases in the territory of the Russian Federation. The authors analyzed domestic articles on gene polymorphisms and their association with various conditions. A systematic review of scientific papers was carried out using the following electronic databases: Cyberleninka, Electronic Library and Google Scholar, which searched for glutathione transferase (GST) gene polymorphisms from 1900 to 2020. The following keywords were used for the search: “GST polymorphism”. The search for articles was carried out in English but took into account the results obtained only in the territory of the Russian Federation. The search for scientific publications was independently checked and compared to filter out duplicate articles. The sample size, the number of loci included in the analysis, and the analyzed population (ethnic group) are essential in studying the relationship between glutathione S-transferase gene polymorphisms and the development of diseases. In general, the analysis of the articles makes it possible to reveal the association between the polymorphisms of the glutathione-S-transferase genes and the high risk of developing oncological diseases, respiratory diseases and other pathologies. This article did not consider the relationship of polymorphisms with reproductive pathologies because this topic includes a large amount of work and requires separate consideration. The least studied issue is the relationship between polymorphisms of genes for biotransformation of xenobiotics and the development of occupational diseases.

show abstract

Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility

Abstract: of the significant factors of the genetic susceptibility to cancer is the inherited differences in the potential of the xenobiotic-metabolizing enzymes. Moreover, glutathione S-transferases (GSTs) have been considered the phase II enzymes that contribute to detoxifying various toxic and

Cited by 13 publications

References 32 publications

Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study

Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment

The relationship of polymorphic variants of genes GSTM1, GSTT1, GSTP1 with the risk of developing diseases (literature review)

Contact Info

Product

Resources

About